EU expands Sotyktu label to adults with active psoriatic arthritis: full analysis
Bristol Myers Squibb has secured European Commission approval for Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, marking another regulatory win for the oral TYK2 inhibitor. The new EU indication covers use alone or in combination with methotrexate in adults who had an inadequate response to, or were intolerant of, prior DMARD therapy. (news.bms.com)
The approval builds on Sotyktu’s earlier European authorization in plaque psoriasis, granted in March 2023, and follows the CHMP’s positive opinion issued on March 26, 2026. In other words, the EC decision converts a favorable scientific recommendation into a market-wide authorization across the EU, though country-level access will still depend on local reimbursement and pricing processes. (ema.europa.eu)
Bristol Myers Squibb said the decision was backed by data from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 trials, which evaluated once-daily Sotyktu 6 mg in adults with active psoriatic arthritis. The company previously reported positive topline results from both studies in 2024, and later presented late-breaking Phase 3 data from POETYK PsA-1 in 2025, describing a safety profile through 16 weeks that was consistent with prior experience in psoriasis and earlier psoriatic arthritis studies. (news.bms.com)
In its approval announcement, BMS framed the decision as an advance for patients dealing with both joint and skin manifestations of disease. The company also emphasized Sotyktu’s mechanism: selective targeting of TYK2, a signaling pathway tied to IL-23, IL-12, and type 1 interferons, which are implicated in psoriatic disease. Frank Behrens, a rheumatologist at Goethe-University Hospital Frankfurt, said in the company release that psoriatic arthritis can present with both widespread musculoskeletal inflammation and difficult skin symptoms, underscoring the need for additional treatment options. (news.bms.com)
Industry context matters here. The U.S. FDA also approved Sotyktu for adults with active psoriatic arthritis in March 2026, making the EU decision part of a broader regulatory expansion rather than a standalone event. That gives BMS a stronger platform to position Sotyktu as a cross-indication immunology brand spanning dermatology and rheumatology, with oral administration as a key commercial differentiator in a market still dominated by injectable biologics. (drugs.com)
Why it matters: For veterinary professionals, this isn’t about immediate clinical crossover, but about where immunology innovation is heading. Human drug development often signals which pathways, modalities, and commercial strategies may later influence animal health R&D. A successful TYK2 franchise in psoriasis and psoriatic arthritis could reinforce interest in more selective intracellular immune modulation, especially where developers want oral options with broad inflammatory relevance. It also highlights how companies are extending assets across adjacent immune-mediated indications to maximize value from a single mechanism. (news.bms.com)
What to watch: The next phase is less about regulatory risk and more about access and uptake. BMS has already noted that pricing and reimbursement negotiations in individual European countries could delay or limit commercial potential, so the practical impact of this approval will hinge on formulary decisions, physician adoption, and how strongly Sotyktu competes against established biologics and other targeted oral therapies in PsA. (news.bms.com)